Relief Therapeutics Aktie [WKN DE: A1H80W / ISIN: CH0100191136]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Relief Therapeutics

08.12.22		Relief Therapeutics Announces Executive Leadership Team Changes (EQS Group)
21.11.22		APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival (PR Newswire)
21.11.22		APR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film Festival (EQS Group)
14.11.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements (EQS Group)
08.11.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, inc. further extend their stay of pending litigation to provide additional time for the parties to finalize their litigation settlement (EQS Group)
07.11.22		Relief Therapeutics Announces Six-Month Stability Data on a New Formulation of RLF-100 (Aviptadil) (EQS Group)
26.10.22		RELIEF THERAPEUTICS Holding SA and NRx Pharmaceuticals, Inc. extend their stay of pending litigation to provide additional time for the parties to finalize their settlement (EQS Group)
25.10.22		Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission (EQS Group)
14.10.22		Relief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating Officer (EQS Group)
10.10.22		Relief Announces U.S. Launch of PKU GOLIKE (EQS Group)
06.10.22		Relief Announces Exclusive Distributor for PKU GOLIKE in the U.S. (EQS Group)
03.10.22		Acer Therapeutics and Relief Therapeutics Announce Receipt of Notice of Allowance of US Patent Application Covering a Kit Comprising Phenylbutyrate and Sodium Benzoate (EQS Group)
22.09.22		Relief Therapeutics Announces IRB Approval and Initiation of an Investigator Initiated Trial of Nexodyn for Epidermolysis Bullosa at Ann & Robert H. Lurie Children's Hospital of Chicago (EQS Group)
15.09.22		Relief Reports Half-Year 2022 Results and Provides Corporate Update (EQS Group)
12.09.22		Relief Therapeutics to Participate in the 22nd Annual Biotech in Europe Forum (EQS Group)
07.09.22		Relief Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference (EQS Group)
24.08.22		Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission (EQS Group)
22.08.22		Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. announce tentative settlement of pending litigation (EQS Group)
17.08.22		Relief Therapeutics Appoints David McCullough as Head of U.S. Market Access (EQS Group)
12.08.22		Relief Therapeutics and Acer Therapeutics Announce that the European Commission Has Granted Orphan Drug Designation for ACER-001 in Maple Syrup Urine Disease (EQS Group)
03.08.22		Relief Therapeutics Announces Promising Initial Stability Data on a New Formulation of RLF-100® (Aviptadil) (EQS Group)
28.07.22		Acer Therapeutics and Relief Therapeutics Announce ACER-001 IND Submission for the Treatment of Maple Syrup Urine Disease (EQS Group)
28.07.22		Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs (EQS Group)
21.07.22		Relief Therapeutics Announces Effectiveness of Registration Statement on Form 20-F (EQS Group)
18.07.22		Relief Therapeutics Announces that its Collaboration Partner has Resubmitted the ACER-001 (sodium phenylbutyrate) New Drug Application (NDA) to the FDA for the treatment of urea cycle disorders (UCDs) (EQS Group)
18.07.22		Relief Therapeutics Appoints Serene Forte, Ph.D., MPH, as Senior Vice President, Head of Genetic Medicine (EQS Group)
13.07.22		Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU (EQS Group)
08.07.22		Acer Therapeutics and Relief Therapeutics Announce That the China National Intellectual Property Administration (CNIPA) Issued Utility Model Patent 11,202,767 Covering ACER-001 Dosage Form (EQS Group)
04.07.22		Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission (EQS Group)
04.07.22		Relief Reports that its U.S. Collaboration Partner has Announced that the FDA has Declined Emergency Use Authorization for Aviptadil for a Subgroup of Patients with Critical COVID-19 at Immediate Risk (EQS Group)
21.06.22		Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Drug Application (NDA) for ACER-001 (EQS Group)
17.06.22		Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission (EQS Group)
13.06.22		Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthrough Designation for Aviptadil (EQS Group)
01.06.22		Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS Holding SA (EQS Group)
31.05.22		Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update on the U.S. National Institutes of Health (NIH) Study of Intravenous Aviptadil in Critical COVID-19 Patients (EQS Group)
26.05.22		Relief Reports that its U.S. Collaboration Partner Announces Data Safety Monitoring Board (DSMB) Update on the U.S. National Institutes of Health (NIH) Study of aviptadil in Critical COVID-19 (EQS Group)
23.05.22		Relief Therapeutics Expands U.S. Commercial Team (EQS Group)
11.05.22		Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission (EQS Group)
09.05.22		Relief Therapeutics to Participate in Industry and Investor Conferences in May (EQS Group)
06.05.22		Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference (EQS Group)
06.05.22		Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA (EQS Group)
27.04.22		Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R) (EQS Group)
26.04.22		Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing (EQS Group)
22.04.22		Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil (EQS Group)
12.04.22		Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting (EQS Group)
05.04.22		Relief Therapeutics Reports Execution of Stipulation with NeuroRx and Jonathan Javitt to Continue Mediation Process (EQS Group)
01.04.22		Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis' (EQS Group)
01.04.22		Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19 (EQS Group)
31.03.22		Relief Reports Full-Year 2021 Results and Provides Corporate Update (EQS Group)
28.03.22		Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using Its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU (EQS Group)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Pierer-Aktie letztlich zweistellig höher: KTM ist insolvent - Antrag auf Sanierung in Eigenverwaltung

Ripple steigt deutlich: Neues ATH noch in 2024?

voestalpine-Aktie zieht an: Erste Group stuft Aktie von "Accumulate" auf "Buy" hoch

Solana Kurs Prognose: 300 US-Dollar noch in diesem Jahr?

Diese Aktien empfehlen Experten zu kaufen

Pierer Mobility-Aktie unter Druck: KTM-Pleite - Schockstarre in der Region und bei den Zulieferern - Land OÖ signalisiert Bereitschaft Beschäftigten zu helfen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	03.12.2024 03:26
Kaufwert:	EUR
	Hinzufügen Speichern